Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HYZN, FB and SBTX

NEW YORK, NY / ACCESSWIRE / November 16, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Hyzon Motors Inc. f/k/a Decarbonization Plus Acquisition Corporation (NASDAQ:HYZN)
Class Period: February 9, 2021 - September 27, 2021
Lead Plaintiff Deadline: November 29, 2021

Throughout the class period, Hyzon Motors Inc. f/k/a Decarbonization Plus Acquisition Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Hyzon was misrepresenting the nature of its "customer" contracts and severely embellished its "deals" and "partnerships" with customers; (2) Hyzon could not deliver its announced vehicles in 2021, on its stated timeline; and (3) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Learn about your recoverable losses in HYZN: https://www.kleinstocklaw.com/pslra-1/hyzon-motors-inc-f-k-a-decarbonization-plus-acquisition-corporation-loss-submission-form?id=21258&from=1

Meta Platforms, Inc. f.k.a. Facebook, Inc. (NASDAQ:FB)
Class Period: November 3, 2016 - October 4, 2021
Lead Plaintiff Deadline: December 27, 2021

According to the complaint, Meta Platforms, Inc. f.k.a. Facebook, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Facebook misrepresented its user growth; (2) Facebook knew, or should have known, that duplicate accounts represented a greater portion of its growth than stated, and it should have provided more detailed disclosures as to the implication of duplicate accounts to Facebook's user base and growth; (3) Facebook did not provide a fair platform for speech, and regularly protected high profile users via its Cross Check/XCheck system; (4) despite being aware of their use of Facebook's platforms, the Company failed to respond meaningfully to drug cartels, human traffickers, and violent organizations; (5) Facebook has been working to attract preteens to its platform and services; and (6) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in FB: https://www.kleinstocklaw.com/pslra-1/facebook-inc-loss-submission-form?id=21258&from=1

Silverback Therapeutics, Inc. (NASDAQ:SBTX)
This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Silverback common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about December 3, 2020 and/or (b) Silverback securities between December 3, 2020 and September 10, 2021, both dates inclusive.
Lead Plaintiff Deadline: January 4, 2022

The SBTX lawsuit alleges that Silverback Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Silverback's lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

Learn about your recoverable losses in SBTX: https://www.kleinstocklaw.com/pslra-1/silverback-therapeutics-inc-loss-submission-form?id=21258&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/673190/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-HYZN-FB-and-SBTX

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.